Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H32N4O4 |
Molecular Weight | 476.5674 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@@H](N1CC[C@](N)(C1=O)C2=CC=C(OCC3=CC(C)=NC4=CC=CC=C34)C=C2)C(=O)NO
InChI
InChIKey=QVNZBDLTUKCPGJ-SHQCIBLASA-N
InChI=1S/C27H32N4O4/c1-17(2)14-24(25(32)30-34)31-13-12-27(28,26(31)33)20-8-10-21(11-9-20)35-16-19-15-18(3)29-23-7-5-4-6-22(19)23/h4-11,15,17,24,34H,12-14,16,28H2,1-3H3,(H,30,32)/t24-,27-/m1/s1
Molecular Formula | C27H32N4O4 |
Molecular Weight | 476.5674 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter-based drug-drug interaction case study. | 2007 Jun |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:06:24 GMT 2023
by
admin
on
Sat Dec 16 09:06:24 GMT 2023
|
Record UNII |
2X066A8676
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
611227-74-8
Created by
admin on Sat Dec 16 09:06:24 GMT 2023 , Edited by admin on Sat Dec 16 09:06:24 GMT 2023
|
PRIMARY | |||
|
9847838
Created by
admin on Sat Dec 16 09:06:24 GMT 2023 , Edited by admin on Sat Dec 16 09:06:24 GMT 2023
|
PRIMARY | |||
|
SUB33630
Created by
admin on Sat Dec 16 09:06:24 GMT 2023 , Edited by admin on Sat Dec 16 09:06:24 GMT 2023
|
PRIMARY | |||
|
100000127545
Created by
admin on Sat Dec 16 09:06:24 GMT 2023 , Edited by admin on Sat Dec 16 09:06:24 GMT 2023
|
PRIMARY | |||
|
2X066A8676
Created by
admin on Sat Dec 16 09:06:24 GMT 2023 , Edited by admin on Sat Dec 16 09:06:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
SELECTIVE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||